AppLovin’s Rally Hits a Rough Patch
After an extraordinary run that sent shares soaring nearly 300% over the past year, AppLovin suddenly lost momentum in early October. The sell-off came as a shock to investors who had watched the ad-tech company become one of Wall Street’s brightest stars.
The trigger was a Bloomberg report revealing that the SEC had opened an investigation into AppLovin’s data-collection practices.
» Read more about: AppLovin’s Rally Hits a Rough Patch »
Read More
Palantir’s Run Feels Unstoppable, But for How Long?
Palantir Technologies (NYSE: PLTR), the data analytics powerhouse, has been one of Wall Street’s most explosive success stories. Since its direct listing in late 2020 at $10 a share, the stock has soared by almost 18-fold gain. Over that same stretch, the S&P 500 hasn’t even doubled.
That kind of outperformance doesn’t happen by accident.
» Read more about: Palantir’s Run Feels Unstoppable, But for How Long? »
Read More
Can You Retire On UPS?
United Parcel Service has long been one of the world’s most trusted shipping giants, a backbone of global commerce that seems almost untouchable. But in the past half decade, shareholders have felt more turbulence than smooth sailing. The stock is down 46%.
That’s a sobering reality for a company many once viewed as a safe,
» Read more about: Can You Retire On UPS? »
Read More
UnitedHealth Could Get Worse Before It Gets Better
After a punishing first half of the year, UnitedHealth’s latest earnings report delivered another gut punch.
The stock, which had already been cut in half year-to-date by July 31, slid even further following the release.
Between deteriorating fundamentals, mounting regulatory pressure, and a brutal earnings revision, it’s fair to ask whether UnitedHealth finally hit bottom,
» Read more about: UnitedHealth Could Get Worse Before It Gets Better »
Read More
Why Buffett’s Buying This Beer Stock
In the second quarter, Warren Buffett quietly added nearly 1.4 million shares of Constellation Brands, bringing Berkshire Hathaway’s total stake to roughly just shy of $2 billion.
That’s a bold move at a time when the entire alcohol industry is facing a slump in consumption. But if history is any guide, Buffett tends to buy when sentiment is sour and value hides in plain sight.
» Read more about: Why Buffett’s Buying This Beer Stock »
Read MoreThe Ivy
1 Infrastructure Specialist That’s Suddenly on Sale
Once investors saw how fast CoreWeave revenues were accelerating, hesitation disappeared. Shares didn’t just climb, they exploded, rising more than 4x in a matter of weeks.
That kind of surge rarely lasts forever, and over the past month CoreWeave has given back roughly 35%. The pullback has left investors wondering whether something fundamental has changed or whether this is simply the kind of temporary reset that follows massive gains.
» Read more about: 1 Infrastructure Specialist That’s Suddenly on Sale »
Read MoreThe Spotlight
Why Novo May Be the Real Winner in Obesity Drug Boom
For decades, Novo Nordisk was known mainly within the medical community as a quiet Danish powerhouse in diabetes care. Fast-forward to today, and its brand names are practically pop culture references. Wegovy and Ozempic have become synonymous with rapid weight loss, with late-night comedians, TikTok influencers, and even Hollywood scripts weaving them into conversation. Yet the company’s stock,
» Read more about: Why Novo May Be the Real Winner in Obesity Drug Boom »
Read MoreThe Daily
Equity mutual fund inflows rise 21% in November; debt fund flows moderate
In November 2025, mutual funds in India saw net equity inflows of ₹29,894 crore, marking a 21% increase from ₹24,671 crore in October, according to the latest data from the Association of Mutual Funds in India (AMFI). Total assets under management (AUM) rose to ₹80.80 lakh crore from ₹79.87 lakh crore in the previous month,
» Read more about: Equity mutual fund inflows rise 21% in November; debt fund flows moderate »